Press Releases

Jan. 12 Novocure Announces Preliminary Full Year and Fourth Quarter 2025 Performance and Provides Company Update BU
Dec. 22 Novocure to Present at 44th Annual J.P. Morgan Healthcare Conference BU
Dec. 01 Novocure Appoints Company President Frank Leonard as Chief Executive Officer BU
Nov. 26 Novocure to Participate in 37th Annual Piper Sandler Healthcare Conference BU
Nov. 12 Novocure to Participate in 2025 Jefferies Global Healthcare Conference BU
25-10-30 NovoCure: Q3 Earnings Snapshot AQ
25-10-30 Novocure Reports Third Quarter 2025 Financial Results BU
25-10-16 Novocure to Present New Research for Tumor Treating Fields Therapy at European Association of Neuro-Oncology Meeting and the European Society for Medical Oncology Congress AQ
25-10-15 Novocure to Present New Research for Tumor Treating Fields (TTFields) Therapy at European Association of Neuro-Oncology (EANO) Meeting and the European Society for Medical Oncology (ESMO) Congress BU
25-10-01 Novocure to Report Third Quarter 2025 Financial Results BU
25-09-29 Novocure to Present Final Results from the Pivotal Phase 3 METIS Trial of its Tumor Treating Fields (TTFields) Therapy for Brain Metastases from Non-Small Cell Lung Cancer at 2025 ASTRO Annual Meeting BU
25-09-15 Novocure’s Optune Lua® Receives Approval in Japan for the Treatment of Unresectable Advanced/Recurrent Non-Small Cell Lung Cancer (NSCLC) BU
25-08-28 Novocure Announces Upcoming Investor Events BU
25-08-25 Novocure Announces Coverage of Tumor Treating Fields (TTFields) Therapy for Patients with Newly Diagnosed Glioblastoma in Spain BU
25-08-20 Novocure Submits Premarket Approval Application to FDA for Tumor Treating Fields Therapy in Locally Advanced Pancreatic Cancer BU
25-07-25 NovoCure: Q2 Earnings Snapshot AQ
25-07-24 Novocure Reports Second Quarter 2025 Financial Results BU
25-07-01 Novocure to Present Final Secondary Endpoint Data from the Phase 3 PANOVA-3 Trial of Tumor Treating Fields (TTFields) in Pancreatic Cancer at the ESMO Gastrointestinal Cancers Congress 2025 BU
25-06-30 Novocure to Report Second Quarter 2025 Financial Results BU
25-05-31 Results From the Phase 3 PANOVA-3 Trial of Novocure’s Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting BU
25-05-27 Novocure Announces Upcoming Investor Events BU
25-04-24 NovoCure: Q1 Earnings Snapshot AQ
25-04-24 Novocure Reports First Quarter 2025 Financial Results BU
25-04-23 Novocure to Present Results from the Phase 3 PANOVA-3 Clinical Trial of its Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer as a Late-Breaking Oral Presentation at the 2025 ASCO Annual Meeting BU
25-04-22 Novocure’s Optune Lua® Receives CE Mark Approval for the Treatment of Metastatic Non-Small Cell Lung Cancer BU
No results for this search